{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:33:24Z","timestamp":1791275604380,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40119-015-0036-0","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T08:08:46Z","timestamp":1427443726000},"page":"5-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Review of the Key Clinical Trials of 2014"],"prefix":"10.1007","volume":"4","author":[{"given":"Peter","family":"McKavanagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian B.","family":"Menown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"36_CR1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.108.792564","volume":"119","author":"V Fuster","year":"2009","unstructured":"Fuster V, van der Zee S, Elmariah S, Bonow RO. Careers in cardiovascular research. Circulation. 2009;119:754\u201360.","journal-title":"Circulation"},{"issue":"11","key":"36_CR2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, PARADIGM-HF Investigators and Committees, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"key":"36_CR3","doi-asserted-by":"crossref","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. for the CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2014. pii:ehu385 (Epub ahead of print).","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"36_CR4","doi-asserted-by":"crossref","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; the OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2014.","DOI":"10.1056\/NEJMoa1410853"},{"issue":"25","key":"36_CR5","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","volume":"101","author":"MG Sutton","year":"2000","unstructured":"Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981\u20138.","journal-title":"Circulation"},{"key":"36_CR6","unstructured":"Abraham W. Percutaneous ventricular restoration therapy using the parachute device in patients with ischemic dilated heart failure: pooled analysis of the first 100 patients treated for 1\u00a0year. In: Presented at European Society of Cardiology Heart Failure Association, May 19, Athens, Greece. 2014."},{"key":"36_CR7","unstructured":"CardioKinetix, Inc. The Parachute left ventricular device. Reproduced with permission from www.cardiokinetix.com . Accessed 28 Feb 2015."},{"issue":"12","key":"36_CR8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJMoa1305520","volume":"369","author":"DS Wald","year":"2013","unstructured":"Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115\u201323.","journal-title":"N Engl J Med"},{"key":"36_CR9","unstructured":"Gershlick AH. Complete versus Lesion only PRimary -PCI Trial (CvLPRIT): treat the infarct related artery only or all lesions. In: Presented at European Society of Cardiology, September 1, Barcelona, Spain. 2014."},{"key":"36_CR10","unstructured":"Oldroyd, K. Preventive Angioplasty in Acute Myocardial Infarction. In: Presented at Society for Cardiovascular Angiography and Interventions (SCAI) 2014 Annual Scientific Sessions, May 30, Las Vegas, Nevada, USA. 2014."},{"issue":"1","key":"36_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2013.09.018","volume":"167","author":"KR Bainey","year":"2014","unstructured":"Bainey KR, Mehta SR, Lai T, Welsh RC. Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Am Heart J. 2014;167(1):1\u201314.","journal-title":"Am Heart J."},{"key":"36_CR12","unstructured":"Complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary interventions for ST-segment elevation myocardial infarction (COMPLETE) trial. http:\/\/www.controlled-trials.com\/isrctn\/pf\/21662248 . Accessed 28 Feb 2015."},{"issue":"17","key":"36_CR13","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1308789","volume":"369","author":"O Fr\u00f6bert","year":"2013","unstructured":"Fr\u00f6bert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. Thrombus aspiration during ST-segment elevation myocardial infarction (TASTE Trial). N Engl J Med. 2013;369(17):1587\u201397.","journal-title":"N Engl J Med"},{"issue":"12","key":"36_CR14","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1405707","volume":"371","author":"B Lagerqvist","year":"2014","unstructured":"Lagerqvist B, Fr\u00f6bert O, Olivecrona GK, Gudnason T, Maeng M, Alstr\u00f6m P, et al. Outcomes 1\u00a0year after thrombus aspiration for myocardial infarction. N Engl J Med. 2014;371(12):1111\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"36_CR15","doi-asserted-by":"crossref","first-page":"597.e1","DOI":"10.1016\/j.ahj.2005.11.010","volume":"151","author":"T Svilaas","year":"2006","unstructured":"Svilaas T, van der Horst IC, Zijlstra F. Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)\u2014study design. Am Heart J. 2006;151(3):597.e1\u20137.","journal-title":"Am Heart J."},{"key":"36_CR16","unstructured":"Pilgrim T, Heg D, Roffi M, T\u00fcller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014. pii:S0140-6736(14)61038-2 (epub ahead of print)."},{"issue":"8","key":"36_CR17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcin.2013.04.011","volume":"6","author":"PW Serruys","year":"2013","unstructured":"Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, J\u00fcni P, Windecker S. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6(8):777\u201389.","journal-title":"JACC Cardiovasc Interv."},{"issue":"11","key":"36_CR18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2014.05.012","volume":"64","author":"GL Bakris","year":"2014","unstructured":"Bakris GL, Townsend RR, Liu M, Cohen SA, D\u2019Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"114","key":"36_CR19","first-page":"05010","volume":"17","author":"M B\u00f6hm","year":"2015","unstructured":"B\u00f6hm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G, on behalf of the GSR Investigators. First Report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;17(114):05010.","journal-title":"Hypertension"},{"key":"36_CR20","doi-asserted-by":"crossref","unstructured":"Schwandt P, Scholze JE, Bertsch T, Liepold E, Haas GM. Blood pressure percentiles in 22,051 German children and adolescents: the PEP Family Heart Study. Am J Hypertens. 2014. pii:hpu208 (epub ahead of print).","DOI":"10.1093\/ajh\/hpu208"},{"key":"36_CR21","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155\u201366.","journal-title":"N Engl J Med"},{"key":"36_CR22","unstructured":"Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti M, Salvatella N, et al. Second generation drug-eluting stents implantation followed by six versus twelve-month\u2014dual antiplatelet therapy\u2014the Security Randomized Clinical Trial. J Am Coll Cardiol. 2014. Pii:S0735-1097(14)06155-5."},{"issue":"37","key":"36_CR23","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC\/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541\u2013619.","journal-title":"Eur Heart J"},{"key":"36_CR24","doi-asserted-by":"crossref","unstructured":"Schulz-Sch\u00fcpke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, T\u00f6lg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, W\u00f6hrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Sch\u00f6mig A, Mehilli J, Kastrati A; on behalf of the Intracoronary Stenting and Antithrombotic Regimen. Safety and Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) trial investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12\u00a0months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015. pii:ehu523 (epub ahead of print).","DOI":"10.1093\/eurheartj\/ehu523"},{"key":"36_CR25","doi-asserted-by":"crossref","unstructured":"Montalescot G, van \u2018t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016\u201327.","DOI":"10.1056\/NEJMoa1407024"},{"key":"36_CR26","doi-asserted-by":"crossref","unstructured":"Bagai A, Peterson ED, Honeycutt E, Effron MB, Cohen DJ, Goodman SG, Anstrom KJ, Gupta A, Messenger JC, Wang TY. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care. 2014. pii:2048872614564082 (epub ahead of print).","DOI":"10.1177\/2048872614564082"},{"key":"36_CR27","doi-asserted-by":"crossref","unstructured":"Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al; on behalf of the X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014. pii:ehu367. (epub ahead of print).","DOI":"10.1093\/eurheartj\/ehu367"},{"issue":"17","key":"36_CR28","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.114.009834","volume":"130","author":"SR Kapadia","year":"2014","unstructured":"Kapadia SR, Tuzcu EM, Makkar RR, Svensson LG, Agarwal S, Kodali S, et al. Long-term outcomes of inoperable patients with aortic stenosis randomly assigned to transcatheter aortic valve replacement or standard therapy. Circulation. 2014;130(17):1483\u201392.","journal-title":"Circulation"},{"issue":"19","key":"36_CR29","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","volume":"370","author":"DH Adams","year":"2014","unstructured":"Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, U.S. CoreValve Clinical Investigators, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790\u20138.","journal-title":"N Engl J Med"},{"issue":"11","key":"36_CR30","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.amjcard.2014.03.014","volume":"113","author":"D Capodanno","year":"2014","unstructured":"Capodanno D, Barbanti M, Tamburino C, D\u2019Errigo P, Ranucci M, Santoro G, OBSERVANT Research Group, et al. A simple risk tool (the OBSERVANT score) for prediction of 30-day mortality after transcatheter aortic valve replacement. Am J Cardiol. 2014;113(11):1851\u20138.","journal-title":"Am J Cardiol"},{"key":"36_CR31","unstructured":"Barbanti M. The OBSERVANT registry 1\u00a0year result. In: Presented at Transcatheter Cardiovascular Therapeutics, September 16, Washington, DC, USA. 2014."},{"key":"36_CR32","unstructured":"The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01314313?term=partner+AND+sapien&rank=2 . Accessed 28 Feb 2015."},{"key":"36_CR33","unstructured":"Safety and Efficacy Study of the Medtronic CoreValve\u00ae System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01586910?term=SURTAVI&rank=1 . Accessed 28 Feb 2015."},{"issue":"19","key":"36_CR34","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","volume":"30","author":"K Fox","year":"2009","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337\u201345.","journal-title":"Eur Heart J"},{"issue":"12","key":"36_CR35","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M. Ferrari R; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091\u20139.","journal-title":"N Engl J Med"},{"key":"36_CR36","unstructured":"Baptista S. POST-IT (Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease) registry. In: Presented at Congress of the European Association of Percutaneous Cardiovascular Interventions, Paris, France. 2014."},{"issue":"13","key":"36_CR37","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1408758","volume":"371","author":"B Bruyne De","year":"2014","unstructured":"De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, the FAME 2 Trial Investigators, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371(13):1208\u201317.","journal-title":"N Engl J Med."},{"key":"36_CR38","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140\u201350.","journal-title":"N Engl J Med"},{"key":"36_CR39","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539\u201349.","journal-title":"N Engl J Med"},{"key":"36_CR40","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/europace\/euq146","volume":"12","author":"L Bisch","year":"2010","unstructured":"Bisch L, Da Costa A, Dauphinot V, Romeyer-Bouchard C, Khris L, M\u2019Baye A, et al. Predictive factors of difficult implantation procedure in cardiac resynchronization therapy. Europace. 2010;12:1141\u20138.","journal-title":"Europace."},{"key":"36_CR41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJM200103223441202","volume":"344","author":"S Cazeau","year":"2001","unstructured":"Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873\u201380.","journal-title":"N Engl J Med"},{"key":"36_CR42","unstructured":"Boriani G. Cardiac resynchronization therapy with a novel quadripolar lead decreases complications at six months: preliminary results of the MORE-CRT trial. In: Presented at European Society of Cardiology, August 31, Barcelona, Spain. 2014."},{"key":"36_CR43","unstructured":"St. Jude Medical products. The Leadless Pacemaker. http:\/\/www.sjm.com\/leadlesspacing\/intl\/options\/leadless-pacing . Accessed 28 Feb 2015."},{"issue":"14","key":"36_CR44","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1161\/CIRCULATIONAHA.113.006987","volume":"129","author":"VY Reddy","year":"2014","unstructured":"Reddy VY, Knops RE, Sperzel J, Miller MA, Petru J, Simon J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation. 2014;129(14):1466\u201371.","journal-title":"Circulation"},{"issue":"2","key":"36_CR45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1160\/TH4-04-0383","volume":"112","author":"C Martinez","year":"2014","unstructured":"Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost. 2014;112(2):276\u201386.","journal-title":"Thromb Haemost."},{"key":"36_CR46","unstructured":"Anguera Camos I. Efficacy of quinidine in patients with Brugada syndrome and frequent ventricular arrhythmia episodes. In: Presented at European Society of Cardiology, August 31, Barcelona, Spain. 2014."},{"key":"36_CR47","unstructured":"Cannon C. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe\/Simvastatin) vs Simvastatin (P04103). In: Presented at American Heart Association, November 18, Chicago, Illinois, USA. 2014."},{"issue":"6","key":"36_CR48","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","volume":"8","author":"PM Moriarty","year":"2014","unstructured":"Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8(6):554\u201361.","journal-title":"J Clin Lipidol."},{"key":"36_CR49","author":"JB Muhlestein","year":"2014","unstructured":"Muhlestein JB, Lapp\u00e9 DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, Vavere AL, Anderson JL. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 Randomized Clinical Trial. JAMA. 2014;. doi: 10.1001\/jama.2014.15825 .","journal-title":"JAMA"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-015-0036-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T09:18:36Z","timestamp":1566465516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40119-015-0036-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s40119-015-0036-0","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}